A Phase 1 interventional study of LY3502970 and Placebo in Overweight and Obesity, sponsored by Eli Lilly and Company. Completed at 3 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.
Among the 22 studies testing orforglipron in Obesity, this one is the 22nd largest by enrollment, is one of 6 that started in 2023, is one of 6 in phase 1, and was the 8th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 10 more countries
Ages 6–17
Eli Lilly and Company · Sites in United States, Israel, Italy and 3 more countries
Ages 12–17
Eli Lilly and Company · Sites in China
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 324 across the 22 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 22 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 114th largest by enrollment of the 117 interventional ones that give a count, is one of 21 that started in 2023, is one of 40 in phase 1, and was the 37th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
5 of the studies testing orforglipron in Obesity that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972459Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 22 studies testing orforglipron in Obesity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive LY3502970, or placebo given orally. For each participant, the study will last about approximately 22- and 30-weeks for both cohort 1 and 2, respectively including screening period.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 24 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 milligram (mg), 3 mg, 6 mg and then 12 mg LY3502970 administered orally once daily (QD) from Day 1 for 16 weeks.
Drug: LY3502970
Participants received LY3502970 with dose escalation every 4 weeks, starting from 1 mg, 3 mg, 6 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD from Day 1 for 24 weeks.
Drug: LY3502970
Participants received placebo administered orally QD.
Drug: Placebo
Administered orally.
Administered orally.
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline through Week 18 (Cohort 1) & Week 26 (Cohort 2)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 at Steady State (Cohort 1)
Pharmacokinetic parameter Cmax (maximum observed plasma concentration) of LY3502970 following multiple oral doses at escalating dose levels. Cmax was assessed at steady state using plasma concentration-time data collected at specified timepoints per protocol.
Time frame: Day 56 and Day 112 (Predose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post dose)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 at Steady State (Cohort 2)
Pharmacokinetic parameter Cmax (maximum observed plasma concentration) of LY3502970 following multiple oral doses at escalating dose levels. Cmax was assessed at steady state using plasma concentration-time data collected at specified timepoints per protocol.
Time frame: Day 28, Day 84, Day 140, and Day 168 (Predose, 0.5, 1, 2, 4, 6, 12, and 24 hours post dose)
PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hour Time Point (AUC0-24) of LY3502970 at Steady State (Cohort 1)
Pharmacokinetic parameter AUC0-24 of LY3502970 following multiple oral doses at escalating dose levels. AUC0-24 was derived using plasma concentration-time data collected at predefined time points over a 24-hour dosing interval at steady state per protocol.
Time frame: Cohort 1: Day 56 and Day 112 (Predose, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours post dose)
PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hour Time Point (AUC0-24) of LY3502970 at Steady State (Cohort 2)
Pharmacokinetic parameter AUC0-24 of LY3502970 following multiple oral doses at escalating dose levels. AUC0-24 was derived using plasma concentration-time data collected at predefined time points over a 24-hour dosing interval at steady state per protocol.
Time frame: Day 28, Day 84, Day 140, and Day 168 (Predose, 0.5, 1, 2, 4, 6, 12, and 24 hours post dose)
PD: Change From Baseline in Body Mass Index
PD: Change from baseline in Body Mass Index calculated as post-baseline value minus baseline value. Negative values indicate a decrease in Body Mass Index.
Time frame: Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)
Pharmacodynamics (PD): Change From Baseline in Body Weight
PD: Change from baseline in body weight calculated as post-baseline value minus baseline value. Negative values indicate a decrease in body weight.
Time frame: Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)
PD: Change From Baseline in Waist Circumference
PD: Change from baseline in Waist Circumference calculated as post-baseline value minus baseline value. Negative values indicate a decrease in Waist Circumference.
Time frame: Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)
PD: Change From Baseline in Fasting Plasma Glucose
PD: Change From Baseline in Fasting Plasma Glucose calculated as post-baseline value minus baseline value. Negative values indicate a decrease from baseline
Time frame: Baseline through 113 Days (Cohort 1) and 169 Days (Cohort 2)
| Milestone | LY3502970 (Cohort 1) | LY3502970 (Cohort 2) | Placebo |
|---|---|---|---|
| Started | 10 | 10 | 4 |
| Received at least 1 dose of study drug | 10 | 10 | 4 |
| Completed | 9 | 9 | 2 |
| Not completed | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 |
| Withdrew: Protocol deviation | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Participants | LY3502970 (Cohort 1) | LY3502970 (Cohort 2) | Placebo |
|---|---|---|---|
| TEAEs | 10 | 8 | 3 |
| SAEs | 0 | 0 | 0 |
Pharmacokinetic parameter Cmax (maximum observed plasma concentration) of LY3502970 following multiple oral doses at escalating dose levels. Cmax was assessed at steady state using plasma concentration-time data collected at specified timepoints per protocol.
| nanogram per millilitre (ng/mL) | LY3502970 (Cohort 1) |
|---|---|
| Day 56 | 17.6 ± 39 |
| Day 112 | 61.3 ± 43 |
Pharmacokinetic parameter Cmax (maximum observed plasma concentration) of LY3502970 following multiple oral doses at escalating dose levels. Cmax was assessed at steady state using plasma concentration-time data collected at specified timepoints per protocol.
| nanogram per millilitre (ng/mL) | LY3502970 (Cohort 2) |
|---|---|
| Day 28 | 5.01 ± 44 |
| Day 84 | 35.1 ± 41 |
| Day 140 | 116 ± 42 |
| Day 168 | 159 ± 41 |
Pharmacokinetic parameter AUC0-24 of LY3502970 following multiple oral doses at escalating dose levels. AUC0-24 was derived using plasma concentration-time data collected at predefined time points over a 24-hour dosing interval at steady state per protocol.
| nanogram *hour per milliliter (ng*h/mL) | LY3502970 (Cohort 1) |
|---|---|
| Day 56 | 266 ± 26 |
| Day 112 | 1010 ± 26 |
Pharmacokinetic parameter AUC0-24 of LY3502970 following multiple oral doses at escalating dose levels. AUC0-24 was derived using plasma concentration-time data collected at predefined time points over a 24-hour dosing interval at steady state per protocol.
| nanogram *hour per milliliter (ng*h/mL) | LY3502970 (Cohort 2) |
|---|---|
| Day 28 | 80.4 ± 42 |
| Day 84 | 520 ± 37 |
| Day 140 | 1650 ± 33 |
| Day 168 | 2620 ± 40 |
PD: Change from baseline in Body Mass Index calculated as post-baseline value minus baseline value. Negative values indicate a decrease in Body Mass Index.
| kilograms per square meter (kg/m²) | LY3502970 (Cohort 1) | LY3502970 (Cohort 2) | Placebo (Cohort 1) | Placebo (Cohort 2) |
|---|---|---|---|---|
| PD: Change From Baseline in Body Mass Index | -2.3046 ± 1.1819 | -3.5964 ± 1.4441 | NA ± NA | NA ± NA |
PD: Change from baseline in body weight calculated as post-baseline value minus baseline value. Negative values indicate a decrease in body weight.
| kilograms (kg) | LY3502970 (Cohort 1) | LY3502970 (Cohort 2) | Placebo (Cohort 1) | Placebo (Cohort 2) |
|---|---|---|---|---|
| Pharmacodynamics (PD): Change From Baseline in Body Weight | -6.156 ± 3.710 | -10.211 ± 4.011 | NA ± NA | NA ± NA |
PD: Change from baseline in Waist Circumference calculated as post-baseline value minus baseline value. Negative values indicate a decrease in Waist Circumference.
| centimeters (cm) | LY3502970 (Cohort 1) | LY3502970 (Cohort 2) | Placebo (Cohort 1) | Placebo (Cohort 2) |
|---|---|---|---|---|
| PD: Change From Baseline in Waist Circumference | -5.778 ± 2.879 | -11.667 ± 3.466 | NA ± NA | NA ± NA |
PD: Change From Baseline in Fasting Plasma Glucose calculated as post-baseline value minus baseline value. Negative values indicate a decrease from baseline
| millimoles per liter (mmol/L) | LY3502970 (Cohort 1) | LY3502970 (Cohort 2) | Placebo (Cohort 1) | Placebo (Cohort 2) |
|---|---|---|---|---|
| PD: Change From Baseline in Fasting Plasma Glucose | -0.50 ± 0.45 | -0.17 ± 0.28 | NA ± NA | NA ± NA |
Collected over Baseline up to 182 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY3502970 (Cohort 1) | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| LY3502970 (Cohort 2) | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Placebo | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Event | LY3502970 (Cohort 1) | LY3502970 (Cohort 2) | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 4/10 | 8/10 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 6/10 | 7/10 | 1/4 |
| Decreased appetiteMetabolism and nutrition disorders | 7/10 | 7/10 | 2/4 |
| Upper respiratory tract infectionInfections and infestations | 4/10 | 6/10 | 2/4 |
| Abdominal distensionGastrointestinal disorders | 3/10 | 5/10 | 0/4 |
| FlatulenceGastrointestinal disorders | 2/10 | 5/10 | 0/4 |
| VomitingGastrointestinal disorders | 4/10 | 5/10 | 0/4 |
| Protein urine presentInvestigations | 0/10 | 3/10 | 2/4 |
| EructationGastrointestinal disorders | 4/10 | 2/10 | 0/4 |
| Abdominal painGastrointestinal disorders | 3/10 | 3/10 | 0/4 |
All enrolled participants.
| Age, Continuous(years) | LY3502970 (Cohort 1) | LY3502970 (Cohort 2) | Placebo | Total |
|---|---|---|---|---|
| Mean | 29.8 ± 5.2 | 29.8 ± 7.6 | 31.5 ± 11.0 | 30.1 ± 7.0 |
| Sex: Female, Male(Participants) | LY3502970 (Cohort 1) | LY3502970 (Cohort 2) | Placebo | Total |
|---|---|---|---|---|
| Female | 2 | 8 | 2 | 12 |
| Male | 8 | 2 | 2 | 12 |
| Ethnicity (NIH/OMB)(Participants) | LY3502970 (Cohort 1) | LY3502970 (Cohort 2) | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 10 | 10 | 4 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | LY3502970 (Cohort 1) | LY3502970 (Cohort 2) | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 10 | 10 | 4 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | LY3502970 (Cohort 1) | LY3502970 (Cohort 2) | Placebo | Total |
|---|---|---|---|---|
| China | 10 | 10 | 4 | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2023 to primary completion in Jul 2024, 10 months.
Results were first posted in Jul 2026, 1 year 11 months after primary completion.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 10 months is above that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron